{"id":29210,"date":"2024-08-20T17:35:54","date_gmt":"2024-08-20T12:05:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=29210"},"modified":"2024-08-21T12:03:07","modified_gmt":"2024-08-21T06:33:07","slug":"pharma-news-for-gilead-sciences-syndax-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca","title":{"rendered":"Gilead\u2019s Livdelzi FDA Approval for Primary Biliary Cholangitis; Incyte and Syndax&#8217;s Niktimvo Approved for Graft-Versus-Host Disease; FDA Lifts Hold on BioNTech and MediLink\u2019s ADC Cancer Trial; FDA Approves IMFINZI for Resectable Lung Cancer; Yutrepia Receives Tentative Approval for PAH and PH-ILD"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f68d3f3e258\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f68d3f3e258\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca\/#Gileads_Livdelzi_Seladelpar_Granted_Accelerated_Approval_for_Primary_Biliary_Cholangitis_by_FDA\" >Gilead\u2019s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by FDA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca\/#Incyte_Syndax_bag_FDA_Approval_for_Potential_Blockbuster_Niktimvo_in_Graft-versus-host_Disease\" >Incyte, Syndax bag FDA Approval for Potential Blockbuster Niktimvo in Graft-versus-host Disease&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca\/#FDA_Lifts_Partial_Hold_on_BioNTech_MediLinks_ADC_Cancer_Trial\" >FDA Lifts Partial Hold on BioNTech, MediLink\u2019s ADC Cancer Trial&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca\/#FDA_Approves_IMFINZI_for_the_Treatment_of_Resectable_Non-Small_Cell_Lung_Cancer_Before_and_After_Surgery\" >FDA Approves IMFINZI for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca\/#FDA_Grants_Tentative_Approval_of_YUTREPIA%E2%84%A2_for_Pulmonary_Arterial_Hypertension_and_PH-ILD\" >FDA Grants Tentative Approval of YUTREPIA\u2122 for Pulmonary Arterial Hypertension and PH-ILD&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-gilead-s-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-fda\"><span class=\"ez-toc-section\" id=\"Gileads_Livdelzi_Seladelpar_Granted_Accelerated_Approval_for_Primary_Biliary_Cholangitis_by_FDA\"><\/span>Gilead\u2019s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by FDA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead Sciences, Inc. has received accelerated approval from the FDA for Livdelzi\u00ae (seladelpar) in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-biliary-cholongitis-pbc-market\">treatment of primary biliary cholangitis (PBC)<\/a>. Livdelzi can be used in combination with ursodeoxycholic acid (UDCA) for adults who have not responded adequately to <a href=\"https:\/\/www.delveinsight.com\/report-store\/udca-market-size-forecast-and-drug-insight\">UDCA<\/a> or as a monotherapy for those who cannot tolerate UDCA. However, it is not recommended for individuals with decompensated cirrhosis.<\/p>\n\n\n\n<p>The accelerated approval is supported by the pivotal Phase III RESPONSE study, where 62% of participants treated with Livdelzi met the primary endpoint of a composite biochemical response at 12 months, compared to 20% in the placebo group. Livdelzi also led to the normalization of alkaline phosphatase (ALP) levels in 25% of participants, while no normalization was observed in the placebo group. Additionally, Livdelzi significantly reduced pruritus, a key secondary endpoint, compared to placebo.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Carol Roberts, President of The PBCers Organization, commented on the approval, saying, &#8220;The availability of a new treatment option that can help reduce this intense itching while also improving biomarkers of active liver disease is a milestone for our community.\u201d Gilead&#8217;s CEO, Daniel O\u2019Day, highlighted the significance of Livdelzi, stating, \u201cPeople living with PBC have been waiting for treatment advancements for many years. Today\u2019s approval of Livdelzi, with its distinct profile, provides them with an important new option.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Livdelzi, an oral PPAR delta agonist, is set to challenge the current PBC standard of care, which often falls short for many patients. The drug has shown a durable efficacy and safety profile across several studies, including the long-term open-label ASSURE study and the ongoing confirmatory Phase III AFFIRM study. The RESPONSE study demonstrated Livdelzi&#8217;s ability to improve both pruritus and key biomarkers of cholestasis, making it a significant advancement in the treatment of PBC.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-incyte-syndax-bag-fda-approval-for-potential-blockbuster-niktimvo-in-graft-versus-host-disease-nbsp\"><span class=\"ez-toc-section\" id=\"Incyte_Syndax_bag_FDA_Approval_for_Potential_Blockbuster_Niktimvo_in_Graft-versus-host_Disease\"><\/span>Incyte, Syndax bag FDA Approval for Potential Blockbuster Niktimvo in Graft-versus-host Disease&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Incyte and Syndax Pharmaceuticals announced FDA approval for Niktimvo (axatilimab-csfr), an innovative anti-CSF-1R antibody for <a href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-market\">chronic graft-versus-host disease (GVHD)<\/a>. This marks Niktimvo as the first anti-CSF-1R antibody approved to target inflammation and fibrosis associated with chronic GVHD. The approval is supported by the pivotal AGAVE-201 study, which demonstrated that Niktimvo provided durable responses across various organs and patient subgroups.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Herv\u00e9 Hoppenot, CEO of Incyte, highlighted the significance of this development, stating, \u201cWith the approval of Niktimvo, patients with chronic GVHD whose disease has progressed after prior therapies now have a new treatment option with a novel mechanism of action.\u201d Similarly, Michael A. Metzger, CEO of Syndax, emphasized, \u201cThe approval of Niktimvo represents a significant treatment advancement for patients with chronic GVHD who have failed at least two lines of previous therapy.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The AGAVE-201 study involved 241 patients with refractory chronic GVHD who had previously received at least two lines of systemic therapy. Results showed that 75% of patients receiving Niktimvo at the approved dose achieved an overall response rate within the first six months, with a median time to response of 1.5 months. However, 44% of patients experienced serious adverse reactions, including infections and respiratory issues. Despite this, the trial&#8217;s findings provide a promising new treatment avenue for this challenging condition.<\/p>\n\n\n\n<p>Niktimvo will be co-commercialized by Incyte and Syndax in the U.S., with Incyte holding exclusive rights outside the U.S. The companies plan to seek approval for smaller vial sizes to facilitate dosing and minimize waste, with an anticipated U.S. launch in early Q1 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-lifts-partial-hold-on-biontech-medilink-s-adc-cancer-trial-nbsp\"><span class=\"ez-toc-section\" id=\"FDA_Lifts_Partial_Hold_on_BioNTech_MediLinks_ADC_Cancer_Trial\"><\/span>FDA Lifts Partial Hold on BioNTech, MediLink\u2019s ADC Cancer Trial&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA&nbsp; has lifted the partial clinical hold on MediLink Therapeutics\u2019 Phase I trial evaluating BNT326\/YL202 (NCT05653752), a HER3-targeting antibody-drug conjugate developed in collaboration with BioNTech SE. This decision follows a comprehensive response from MediLink that included data analysis, updates to the investigator brochure, informed consent forms, and an amended clinical trial protocol with additional risk mitigation measures. The trial will now resume recruitment, focusing on dose levels up to 3 mg\/kg, where safety was manageable and clinical activity promising.<\/p>\n\n\n\n<p>The partial hold was initially imposed due to observed dose-dependent treatment-related adverse events (TRAEs), particularly neutropenia and mucositis. The study sponsor addressed these TRAEs, which are common with established chemotherapies, through proactive measures such as dose adjustments and updated safety protocols. The updated clinical trial protocol includes revised guidance on dose modifications and prophylactic treatments to mitigate these risks.<\/p>\n\n\n\n<p>BioNTech and MediLink remain committed to advancing BNT326\/YL202 for solid tumors with significant unmet medical needs, ensuring patient safety while exploring the potential of this promising candidate.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-imfinzi-for-the-treatment-of-resectable-non-small-cell-lung-cancer-before-and-after-surgery-nbsp-nbsp\"><span class=\"ez-toc-section\" id=\"FDA_Approves_IMFINZI_for_the_Treatment_of_Resectable_Non-Small_Cell_Lung_Cancer_Before_and_After_Surgery\"><\/span>FDA Approves IMFINZI for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery&nbsp;&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AstraZeneca\u2019s IMFINZI (durvalumab) has received FDA approval for the treatment of adult patients with resectable early-stage (IIA-IIIB) <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">non-small cell lung cancer (NSCLC)<\/a> who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. The regimen includes IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.<\/p>\n\n\n\n<p>The approval is supported by positive results from the pivotal AEGEAN trial, published in <em>The New England Journal of Medicine<\/em> in October 2023. The trial&#8217;s interim analysis demonstrated a 32% reduction in the risk of recurrence, progression, or death with the IMFINZI-based regimen compared to chemotherapy alone (EFS hazard ratio of 0.68). Additionally, the final analysis showed a pathologic complete response (pCR) rate of 17.2% with IMFINZI plus neoadjuvant chemotherapy, significantly higher than the 4.3% pCR rate for chemotherapy alone.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>John V. Heymach, MD, PhD, from The University of Texas MD Anderson Cancer Center, highlighted that this approval offers a crucial new treatment option that could become a standard approach for patients with resectable NSCLC, addressing the high recurrence rates seen with current treatments. Dave Fredrickson, Executive Vice President at AstraZeneca, emphasized that this approval extends IMFINZI&#8217;s impact from unresectable Stage III disease to early-stage lung cancer, aligning with their goal of curative treatment.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>IMFINZI is also approved in the UK, Switzerland, and Taiwan for this indication, and regulatory reviews are ongoing in the EU, China, and other regions. As per the PACIFIC Phase III trial, it remains a global standard for unresectable, Stage III NSCLC.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-grants-tentative-approval-of-yutrepia-for-pulmonary-arterial-hypertension-and-ph-ild-nbsp\"><span class=\"ez-toc-section\" id=\"FDA_Grants_Tentative_Approval_of_YUTREPIA%E2%84%A2_for_Pulmonary_Arterial_Hypertension_and_PH-ILD\"><\/span>FDA Grants Tentative Approval of YUTREPIA\u2122 for Pulmonary Arterial Hypertension and PH-ILD&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Liquidia Corporation announced that the FDA granted tentative approval for YUTREPIA (treprostinil) inhalation powder. This therapy is intended for <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-market\">adults with pulmonary arterial hypertension (PAH)<\/a> and pulmonary hypertension associated with <a href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market\">interstitial lung disease (PH-ILD)<\/a>. Tentative approval means that YUTREPIA has met all necessary regulatory standards for quality, safety, and efficacy but must wait for the expiration of exclusivity granted to a competing product before it can receive final approval.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Roger Jeffs, Ph.D., CEO of Liquidia, expressed satisfaction with the FDA&#8217;s acknowledgment of their NDA amendment but voiced disappointment over the FDA granting regulatory exclusivity to United Therapeutics for Tyvaso DPI. This exclusivity covers the chronic use of dry-powder formulations of treprostinil for three years. Liquidia plans to challenge this exclusivity decision to ensure timely patient access to YUTREPIA.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The tentative approval is supported by results from the Phase III INSPIRE trial, which demonstrated that YUTREPIA is safe and well-tolerated for both new users and those switching from nebulized treprostinil. Published findings confirm that YUTREPIA meets regulatory standards for manufacturing and quality. Liquidia remains dedicated to addressing the needs of patients with PAH and PH-ILD and aims to secure final approval for YUTREPIA as soon as possible.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead\u2019s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by FDA Gilead Sciences, Inc. has received accelerated approval from the FDA for Livdelzi\u00ae (seladelpar) in the treatment of primary biliary cholangitis (PBC). Livdelzi can be used in combination with ursodeoxycholic acid (UDCA) for adults who have not responded adequately to UDCA or as a [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":29213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19680,704,16392,349,420,6733,639,18507,499,5789],"industry":[17225],"therapeutic_areas":[17233,17227,17228,17243],"class_list":["post-29210","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-chronic-graft-versus-host-disease","tag-fda","tag-interstitial-lung-disease","tag-latest-pharma-news","tag-news","tag-non-small-cell-lung-cancer","tag-pharma-news","tag-primary-biliary-cholangitis","tag-pulmonary-arterial-hypertension","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Gilead Sciences, Syndax, AstraZeneca<\/title>\n<meta name=\"description\" content=\"Gilead\u2019s Livdelzi, Incyte &amp; Syndax&#039;s Niktimvo, BioNTech and MedLink\u2019s ADC Trial, IMFINZI Lung Cancer Nod, Yutrepia for PAH &amp; PH-ILD\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Gilead Sciences, Syndax, AstraZeneca\" \/>\n<meta property=\"og:description\" content=\"Gilead\u2019s Livdelzi, Incyte &amp; Syndax&#039;s Niktimvo, BioNTech and MedLink\u2019s ADC Trial, IMFINZI Lung Cancer Nod, Yutrepia for PAH &amp; PH-ILD\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-20T12:05:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-21T06:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/20173411\/Pharma-news-for-gilead-sciences-syndax-astrazeneca.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Gilead Sciences, Syndax, AstraZeneca","description":"Gilead\u2019s Livdelzi, Incyte & Syndax's Niktimvo, BioNTech and MedLink\u2019s ADC Trial, IMFINZI Lung Cancer Nod, Yutrepia for PAH & PH-ILD","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Gilead Sciences, Syndax, AstraZeneca","og_description":"Gilead\u2019s Livdelzi, Incyte & Syndax's Niktimvo, BioNTech and MedLink\u2019s ADC Trial, IMFINZI Lung Cancer Nod, Yutrepia for PAH & PH-ILD","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-08-20T12:05:54+00:00","article_modified_time":"2024-08-21T06:33:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/20173411\/Pharma-news-for-gilead-sciences-syndax-astrazeneca.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca","name":"Pharma News | Gilead Sciences, Syndax, AstraZeneca","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/20173411\/Pharma-news-for-gilead-sciences-syndax-astrazeneca.png","datePublished":"2024-08-20T12:05:54+00:00","dateModified":"2024-08-21T06:33:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Gilead\u2019s Livdelzi, Incyte & Syndax's Niktimvo, BioNTech and MedLink\u2019s ADC Trial, IMFINZI Lung Cancer Nod, Yutrepia for PAH & PH-ILD","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-sciences-syndax-astrazeneca#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/20173411\/Pharma-news-for-gilead-sciences-syndax-astrazeneca.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/20173411\/Pharma-news-for-gilead-sciences-syndax-astrazeneca.png","width":772,"height":482,"caption":"Pharma-news-for-gilead sciences-syndax-astrazeneca"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/20173411\/Pharma-news-for-gilead-sciences-syndax-astrazeneca-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic graft-versus-host disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Interstitial lung disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Primary Biliary Cholangitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">chronic graft-versus-host disease<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Interstitial lung disease<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Primary Biliary Cholangitis<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Aug 20, 2024","modified":"Updated on Aug 21, 2024"},"absolute_dates_time":{"created":"Posted on Aug 20, 2024 5:35 pm","modified":"Updated on Aug 21, 2024 12:03 pm"},"featured_img_caption":"Pharma-news-for-gilead sciences-syndax-astrazeneca  \n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=29210"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29210\/revisions"}],"predecessor-version":[{"id":29340,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29210\/revisions\/29340"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29213"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=29210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=29210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=29210"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=29210"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=29210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}